Fludara

Phase 1Small molecule

CCelyad Oncology SA

Fludara is one of 135 small molecule programs targeting Pediatric Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pediatric Solid TumorsActive, not recruiting

NeuroblastomaActive, not recruiting

Myelodysplastic SyndromeRecruiting

Multiple MyelomaActive, not recruiting

Pediatric Solid TumorsPhase 1

Active, not recruiting

NeuroblastomaPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 1

Recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Belamaf

GSK

Phase 3

39 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

24 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Biaxin

AbbVie

Phase 3

15 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 8

Elranatamab

Pfizer

Phase 3

27 9

Vepesid

AAvyxa

Phase 3

17 10

Mozobil

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Active, not recruiting

Neuroblastoma

NCT01822652

Q1 2035

Phase 1Recruiting

Myelodysplastic Syndrome

NCT04167696

Q1 2037

Phase 1Active, not recruiting

Multiple Myeloma

NCT04613557

Phase 1Active, not recruiting

Pediatric Solid Tumors

NCT02932956

Q3 2042

Phase 1Recruiting

Liver Cancer

NCT04715191

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting·CCelyad Oncology SA·Phase 1·NCT04167696·27 enrolled

Cell Therapy1 trial

Adoptive Cell Therapy Across Cancer Diagnoses

Completed·IInge Marie Svane·Phase 1/2·NCT03296137·25 enrolled

Multiple Myeloma1 trial

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting·CCelyad Oncology SA·Phase 1·NCT04613557·18 enrolled

Pediatric Solid Tumors1 trial

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Active, not recruiting·—·Phase 1·NCT02932956·10 enrolled

Neuroblastoma1 trial

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Active, not recruiting·—·Phase 1·NCT01822652·11 enrolled

1 more indication

Liver Cancer1 trial

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

Recruiting·BBaylor College of Medicine·Phase 1·NCT04715191·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Fludara. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludara compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludara. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celyad Oncology SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCelyad Oncology SA

Fludara

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Q1 2035

Q1 2037

Q3 2042

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Cell Therapy1 trial

Multiple Myeloma1 trial

Pediatric Solid Tumors1 trial

Neuroblastoma1 trial

Liver Cancer1 trial

References

Drug Info

Quick Facts

Related News